NNNN Stock Overview

Provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. More details

NNNN fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	1/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue grew by 21.9% over the past year

Risk Analysis

No risks detected for NNNN from our risk checks.

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Anbio Biotechnology Competitors

Price History & Performance

Summary of share price highs, lows and changes for Anbio Biotechnology
Historical stock prices
Current Share Price	US$7.75
52 Week High	US$8.22
52 Week Low	US$5.18
Beta	0
1 Month Change	20.53%
3 Month Change	15.84%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	34.32%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	NNNN	US Biotechs	US Market
7D	0%	2.6%	1.2%
1Y	n/a	-9.1%	12.5%

Return vs Industry: Insufficient data to determine how NNNN performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how NNNN performed against the US Market.

Price Volatility

Is NNNN's price volatile compared to industry and market?
NNNN volatility
NNNN Average Weekly Movement	8.5%
Biotechs Industry Average Movement	12.2%
Market Average Movement	8.0%
10% most volatile stocks in US Market	17.2%
10% least volatile stocks in US Market	4.1%

Stable Share Price: NNNN has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine NNNN's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2021	27	Michael Lau	www.anbio.com

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets.

Anbio Biotechnology Fundamentals Summary

How do Anbio Biotechnology's earnings and revenue compare to its market cap?
NNNN fundamental statistics
Market cap	US$339.06m
Earnings (TTM)	US$2.37m
Revenue (TTM)	US$8.19m

143.4x

P/E Ratio

41.6x

P/S Ratio

Is NNNN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NNNN income statement (TTM)
Revenue	US$8.19m
Cost of Revenue	US$2.30m
Gross Profit	US$5.89m
Other Expenses	US$3.51m
Earnings	US$2.37m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.054
Gross Margin	71.90%
Net Profit Margin	28.99%
Debt/Equity Ratio	0%

How did NNNN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/29 08:23
End of Day Share Price	2025/05/29 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Anbio Biotechnology is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.